611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Inflammatory Bowel Disease, Celiac Are Linked: ReviewCOVID-19 Rates May Be Lower Than Thought for Pregnant WomenAs Postponed Surgeries Resume, Can U.S. Hospitals Handle the Strain?Most Americans Still More Worried About COVID-19 Spread Than the EconomyWhat to Know If You're Headed to College With Asthma or AllergiesCoronavirus Was Already Spreading in U.S. in January: StudyAHA News: Inherited High Cholesterol May Be Common in People With Heart DiseaseDVT Clots Strike Many Critically Ill COVID-19 Patients: StudyYour Eyewear and COVID-19 SafetyPandemic Having More Impact on U.S. Hospitals Than Thought: StudyBig Need for Blood Donations as Postponed Surgeries ResumeAs Hard-Hit Areas of America Show Slowing in Coronavirus Cases, Other Regions See SpikesHydroxychloroquine May Worsen Odds for Cancer Patients With COVID-191 in 10 Hospitalized COVID-19 Patients With Diabetes Dies: StudyAHA News: How Bacteria in Your Gut Interact With the Mind and BodyMusic Might Help Soothe Ailing HeartsCould an Injected Electrode Control Your Pain Without Drugs?100,000 Dead, 40 Million Unemployed: America Hits Grim Pandemic MilestonesFDA Approves IV Artesunate for Severe Malaria'Silent' COVID-19 More Widespread Than ThoughtDrug Combos May Be Advance Against Heart FailurePollen Fragments Linger After Rains, Leaving Allergy Sufferers MiserableA New Hip or Knee Can Do a Marriage Good, Study FindsOnly Half of Americans Say They'd Get a Coronavirus Vaccine: SurveyAlzheimer's Gene Linked to Severe COVID-19 RiskCoronavirus Cases Ticking Upwards in Nearly a Dozen U.S. StatesLockdown Got You Down? Experts Offer Tips to De-StressCould a Hormone Help Spur High Blood Pressure?Nursing Homes Are Ground Zero for COVID-19Getting Back to Work Safely After LockdownRemdesivir Will Not Be Enough to Curb COVID-19, Study FindsOutdoor Swimming Pools Not a COVID-19 Risk: ExpertStrokes Are Deadlier When They Hit COVID-19 PatientsAHA News: How to Accurately Measure Blood Pressure at HomeU.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000During the Pandemic, How Safe Is the Great American Summer Vacation?COVID-19 Damages Lungs Differently From the Flu: StudyMore Evidence Hydroxychloroquine Won't Help, May Harm COVID-19 PatientsYour Sleep Habits May Worsen Your AsthmaExtra Pounds Could Bring More Painful JointsCOVID Can Complicate Pregnancy, Especially If Mom Is ObeseWHO Predicts COVID-19 Will Take Heavy Toll in AfricaCombining Remdesivir With Other Meds Could Boost COVID-Fighting PowerMultiple Sclerosis Ups Odds for Heart Trouble, StrokeAHA News: Not Wanting to Burden Busy Hospitals, She Disregarded Heart Attack SignsExperimental Vaccines Shield Monkeys From CoronavirusHeart Attack Cases at ERs Fall by Half – Are COVID Fears to Blame?Asthma Ups Ventilator Needs of Younger Adults With COVID-19: Study1 in 5 Hospitalized NYC COVID-19 Patients Needed ICU CareObesity Ups Odds for Dangerous Lung Clots in COVID-19 Patients
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

People Mount Strong Immune Responses to Coronavirus, Boding Well for a Vaccine

HealthDay News
by By E.J. Mundell
HealthDay Reporter
Updated: May 18th 2020

new article illustration

MONDAY, May 18, 2020 (HealthDay News) -- As the drive towards a vaccine against the new coronavirus accelerates, there's some good news: People with COVID-19 have robust immune responses against the virus, scientists say.

The researchers based their conclusions after testing immune T-cell counts in 20 patients who recovered from the infection.

"If we had seen only marginal immune responses, we would have been concerned," explained researcher Alessandro Sette. "But what we see is a very robust T-cell response against the spike protein [on the virus' outer shell], which is the target of most ongoing COVID-19 efforts, as well as other viral proteins. These findings are really good news for vaccine development."

Sette is a professor in the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology in California.

Uncertainties as to the nature of the human immune system response to the coronavirus have troubled experts searching for an effective coronavirus vaccine.

"All efforts to predict the best vaccine candidates and fine-tune pandemic control measures hinge on understanding the immune response to the virus," Center co-researcher Shane Crotty said in an institute news release.

"People were really worried that COVID-19 doesn't induce immunity, and reports about people getting reinfected reinforced these concerns," he said.

However, "knowing now that the average person makes a solid immune response should largely put those concerns to rest," Crotty believes.

Trials 'look pretty promising'

Indeed, efforts towards a vaccine have shown promise.

A number of coronavirus vaccines under development "look pretty promising" and one or two could be ready for large-scale testing by July, the director of the U.S. National Institutes of Health said.

"Your big challenge now is to go big and everybody is about ready for that. And we want to be sure that happens in a coordinated way," Dr. Francis Collins told the Associated Press.

And on Monday, the New York Times reported that an experimental vaccine against the new coronavirus appears to be safe and to trigger an immune response, according to results of the first human clinical trial.

The findings from the early-stage trial that started in March included eight healthy people who each received two doses of the vaccine, the Times reported.

The volunteers made antibodies that were able to stop the coronavirus from replicating, and the levels of the antibodies were similar to those in people who've recovered after contracting the virus, according to vaccine maker Moderna.

The company said the next phase of the testing will involve 600 people and is scheduled to begin soon, but U.S. officials have cautioned that it could take a year to 18 months to produce a vaccine that would be widely available, according to the Times.

The La Jolla research does seem to solidify the notion that effective vaccines are possible.

In their research, Sette's group found that all the patients had a strong CD4, or "helper," T-cell response to the new coronavirus. Almost all of them had made CD8, or "killer," T-cells specifically against COVID-19. "Our data show that the virus induces what you would expect from a typical, successful antiviral response," Crotty said.

"We have a solid starting foundation to now ask whether there's a difference in the type of immune response in people who have severe outcomes and require hospitalization versus people who can recover at home or are even asymptomatic," Sette noted.

"But not only that, we now have an important tool to determine whether the immune response in people who have received an experimental vaccine resembles what you would expect to see in a protective immune response to COVID-19, as opposed to an insufficient or detrimental response," he said.

Help from the common cold?

Sette and his team also looked at T-cell responses in blood samples taken before this coronavirus began circulating. They found that many people had a strong immune response even though they had never been exposed.

Because nearly everyone has been exposed to common cold coronaviruses, this might explain this immune response, they said.

It's not clear, however, if this "cross-reactivity" confers some preexisting immunity to COVID-19. But if it does, that might explain why some people or areas are hit harder by COVID-19 than others, the researchers said.

"Given the severity of the ongoing COVID-19 pandemic, any degree of cross-reactive coronavirus immunity could have a very substantial impact on the overall course of the pandemic and is a key detail to consider for epidemiologists as they try to scope out how severely COVID-19 will affect communities in the coming months, Crotty said.

Dr. Amesh Adalja is senior scholar at the Johns Hopkins Center for Health Security. Reading over the La Jolla findings, he said they "establish that the cell-mediated arm of the immune system does provide substantial immunity after infection.

"It also shows that some of the cells that respond to the other, endemic, coronaviruses have cross-reactive potential against this coronavirus," Adalja said. "Vaccine studies will have to look at both antibody generation as well as cell-mediated immunity."

The report was published online May 14 in the journal Cell.

More information

For more on COVID-19, see the U.S. Centers for Disease Control and Prevention.